EBS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EBS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Emergent BioSolutions's yield on cost for the quarter that ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Emergent BioSolutions's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Emergent BioSolutions is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Emergent BioSolutions (NYSE:EBS) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Emergent BioSolutions's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Donald W Degolyer | director | 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Marvin L White | director | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
Kathryn C Zoon | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Neal Franklin Fowler | director | C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
William Hartzel | officer: SVP, Bioservices | 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879 |
Miller H Haywood Iii | officer: Interim CEO | EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879 |
Paul Anthony Williams | officer: SVP, Products Business | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Ronald Richard | director | 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
Sujata Tyagi Dayal | director | C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587 |
Keith Katkin | director | C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Glessner Coleen | officer: EVP, Quality & Ethics, and CPL | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
Jennifer Lynne Fox | officer: EVP, Ext Aff, GC, Corp Sec | 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879 |
Richard S Lindahl | officer: EVP, Chief Financial Officer | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Sue Bailey | director | 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850 |
Adam Havey | officer: EVP, BioDefense Division | 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853 |
From GuruFocus
By GuruFocus News • 11-08-2024
By GuruFocus News • 11-08-2024
By Marketwired • 08-29-2024
By Marketwired • 09-26-2024
By GuruFocus News • 10-09-2024
By Marketwired • 10-08-2024
By GlobeNewswire • 08-19-2024
By GuruFocus News • 11-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.